The Politics of Prescribing
  • Home
  • Author
  • Statement of Intent
  • Blog
  • Media
  • More

Health Canada drug approval system may be harmful to patients

3/7/2013

 
In an interview with Dr. Joel Lexchin, Global News explores the problems with Health Canada's drug approval process.  Health Canada's lack of transparency in terms of the level of data and analysis conducted on summary basis of decisions (SBD) documents.  Furthermore, the quality of the information provided by industry to Health Canada to approve drugs is unknown.

This is reason for concern, says Dr. Lexchin, because Health Canada does not make information during their approval process known to experts or the public.  Given this, medical experts, physicians and the public are not privy to Health Canada's drug approval process and the basis on which drugs are approved for the Canadian market.

A 2012 study by Dr. Lexchin found that Health Canada drugs that were approved after a standard review (300 business days) had a 1/5 (20%) chance of having a serious safety warning after being on the market.  Comparatively, drugs that Health Canada approved after priority review (180 business days) had a 1/3 (33%) chance of having a serious safety warning after release onto the market.

According to the study, the difference in approval times by 120 days is an important factor in determining the likelihood that a drug will be associated with serious safety warnings after its approval by Health Canada.  In the 120 days between the  standard review and priority review times, Health Canada has less time to look at the data and misses information and inferences from data that later result in serious safety warnings and patient harm

New Drugs and SafetyWhat Happened to New Active Substances Approved in Canada Between 1995 and 2010?Transparency in drug regulation: Mirage or oasis?
Provision of information on regulatory authorities’ websites
Who Needs Faster Drug Approval Times in Canada: The Public or the Industry?
Secrecy and the Health Protection Branch
Hear No Secrets, See No Secrets, Speak No Secrets: Secrecy in the Canadian Drug Approval System
Legislative regulation and ethical governance of medical research in different European Union countries

Obat Herbal Diabetes link
28/2/2014 12:59:21 am

Thats a very good system i think


Comments are closed.


    Author:

    Adrienne is currently completing her J.D. (2019) at Osgoode Hall Law School. She received her M.A. (2012) and Ph.D. (2016) in Health Policy & Equity with a focus on pharmaceutical policy, regulation, and patient safety.

    View my profile on LinkedIn

    Archives

    March 2018
    November 2016
    August 2016
    July 2015
    February 2015
    November 2014
    September 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    November 2012
    May 2012
    May 2011
    November 2010

    Categories

    All
    Abbott Laboratories
    Acne Treatments
    Adderall Xr
    Adriane Fugh-Berman
    Adverse Events
    Aggrenox
    Alan Cassels
    Alltrials Petition
    Amgen
    Anna Reid
    Antidepressants
    Apotex
    Aranesp Darbepoetin Alfa
    Arthur Schafer
    Astra Zeneca
    Atrovent Ipratropium
    Australia
    Avandia
    Awareness
    Barbara Mintzes
    Baycol Cerivastatin
    Bayer
    Bextra Valdecoxib
    Birth Control Pills
    Birth Defects
    Boehringer Ingelheim
    Bristolmyers Squibb
    British Columbia
    Cahspr
    Canadas Health Care System
    Canadian Centre For Policy Alternatives Ccpa
    Chspr
    Ciprofloxacin
    Clinical Trial Data
    College Of Pharmacists
    Combivent
    Conference
    Conflicts Of Interest
    Consumer Advocates
    Contract Research Organization Cro
    Crestor Rosuvastatin
    David Healy
    Depakote Divalproex Sodium
    Diabetes
    Diovan Valsartan
    Direct To Consumer Advertising Dtca
    Direct To Physician Advertising Dtpa
    Disease Mongering
    Drug Compounding Companies
    Drug Coverage In Canada
    Drug Manufacturing
    Drug Promotion
    Drug Safety
    Education
    Eli Lilly
    Elsevier
    Erectile Dysfunction Drugs
    Ethics Standards
    European Medicines Agency
    Evidence For Caution
    Financial Reward
    Food And Drug Administration Fda
    Fosamax Alendronate Sodium
    France
    French National Agency Of Medicine And Health Products Safety Ansm
    Geodon
    Ghostwriting
    Glaxosmithkline Gsk
    Gleevec Imatinib
    Health Canada
    Helsinki Declaration
    Hyalgan
    India
    Interviews
    Isotretinoin
    Janssen
    Japan
    Job Cuts
    Joel Lexchin
    Johnson Johnson
    Lescol Fluvastatin
    Lipitor Atorvastatin
    Liptruzet Atorvastatinezetimibe
    Liptruzet Atorvastatin Ezetimibe
    Litigation
    Lopid Gemfibrozil
    Lyrica
    Marc Andre Gagnon
    Marc A Rodwin
    Mediator Benfluorex
    Medical Ghostwriting
    Medical Journals
    Medication Guidelines
    Merck
    Mevacor Lovastatin
    Micardis
    Michael Mcbane
    Myfortic Mycophenolic Acid
    National Institute Of Biological Standards And Control
    Neurontin Gabapentin
    Novartis
    Novo Nordisk
    Nsaids
    Off Label Prescribing
    Open Pharma
    Outsourcing
    Patient Advocacy
    Patient Protection And Affordable Care Act Ppaca
    Patient Safety
    Paxil
    Pfizer
    Pharmacare
    Pharmaceutical Affairs Law
    Pharmaceutical Policy Research Collaboration Pprc
    Pharmacists Planning Services Inc
    Pharmedout
    Physicians
    Pradaxa Dabigatran
    Pravachol Pravastatin
    Prepulsid Cisapride
    Prescrire
    Professional Medical Associations
    Propublica
    Protecting Canadians From Unsafe Drugs Act
    Ranbaxy
    Regeneron Pharmaceutical Inc
    Regulation
    Research And Development
    Research And Development
    Rhabdomyolysis
    Risperdal Risperidone
    Roche
    Romanow Report
    Royal Canadian Mounted Police Rcmp
    Rxiskorg
    Sanofi Aventis
    Selling Sickness
    Seniors
    Sergio Sismondo
    Seroquel Quetiapin
    Shire
    South Korea
    Statins
    Steve Morgan
    Steven Lewis
    Sun Pharma
    Sweden
    Tamiflu
    Tasigna Nilotinib
    Tecfidera Dimethyl Fumarate
    Terence Young
    Therapeutics Initiative
    Trials Tracker
    Tylenol Acetaminophen
    Uk Medicines And Healthcare Products Regulatory Agency Mhra
    Uk National Health Service Nhs
    University Of British Columbia
    University Of Toronto
    Us Centres For Medicare Medicaid
    Us Fdasia
    Us Sunshine Act
    Viagra
    Victoza Liraglutide
    Vioxx Rofecoxib
    Wellbutrin Bupropion
    Women
    Zocor Simvastatin
    Zometa Zoledonic Acid
    Zyprexa Olanzapine
    Zyvox

    RSS Feed

© 2013 - 2018. Adrienne Shnier. Toronto, Canada.
Home
Author
Statement of Intent
Blog
Media
More
✕